ODAC votes down AML drug as FDA raises concerns over equipoise, uncertain efficacy

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

The FDA Oncologic Drugs Advisory Committee May 14 voted 8-3 against approval of quizartinib for the treatment of adults with relapsed or refractory acute myeloid leukemia which is FLT3- ITD positive, as detected by an FDA-approved test.

To access this subscriber-only content please log in or renew you subscription.

Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.

Login Subscribe
Editor & Publisher

YOU MAY BE INTERESTED IN

Editor & Publisher

Login